Ziegler Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Ziegler Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,490	Closed	-$779K	–	425
2023 Q1	$779K	Buy	21,490 +210	+1%	+$8.07K	0.03%	318
2022 Q4	$759K	Sell	21,280 -4,962	-19%	-$172K	0.03%	317
2022 Q3	$888K	Sell	26,242 -154	-0.6%	-$5.01K	0.04%	311
2022 Q2	$763K	Buy	26,396 +719	+3%	+$20.6K	0.03%	331
2022 Q1	$830K	Sell	25,677 -2,100	-8%	-$64.4K	0.04%	318
2021 Q4	$810K	Sell	27,777 -9,060	-25%	-$275K	0.03%	341
2021 Q3	$982K	Buy	36,837 +9,362	+34%	+$251K	0.04%	332
2021 Q2	$846K	Sell	27,475 -881	-3%	-$27K	0.03%	350
2021 Q1	$742K	Sell	28,356 -759	-3%	-$21.2K	0.02%	360
2020 Q4	$733K	Buy	29,115 +5,857	+25%	+$126K	0.02%	358
2020 Q3	$485K	Buy	+23,258	New	+$528K	0.02%	376

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ziegler Capital Management's SUPN Position: Q2 2023 in Review

Ziegler Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 21,490 shares — an estimated $779K sold.

Ziegler Capital Management first reported a position in SUPN in Q3 2020 and held it in 11 quarters. The position peaked at $982K in Q3 2021. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

Ziegler Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ziegler Capital Management sold 21,490 Supernus Pharmaceuticals shares in Q2 2023, an estimated $779K.
Ziegler Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2020 and held it in 11 quarters.
Ziegler Capital Management's Supernus Pharmaceuticals position peaked at $982K in Q3 2021.
249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Ziegler Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.